Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co.

Kepler Capital analyst Torsten Sauter maintained a Buy rating on Logitech on January 27 and set a price target of CHF95.00. The company’s shares cl...

Kepler Capital  Sticks to Its Buy Rating for Logitech (LOGI)

Origin Enterprises plc ( ($GB:OGN) ) has issued an update. Origin Enterprises plc has disclosed that Cobas Asset Management has increased its share...

Cobas Asset Management Lifts Stake in Origin Enterprises to 8.39%

The latest update is out from Origin Enterprises plc ( ($GB:OGN) ). Origin Enterprises has re-issued 1,385 treasury shares to satisfy the exercise ...

Origin Enterprises Issues Treasury Shares to Satisfy Option Awards

Morgan Stanley analyst Erik Woodring downgraded Logitech to a Sell today and set a price target of $89.00. Woodring covers the Technology sector, f...

Morgan Stanley downgrades Logitech (LOGI) to a Sell

Origin Enterprises plc ( ($GB:OGN) ) has issued an announcement. Origin Enterprises plc has reissued 3,500 treasury shares to satisfy the exercise ...

Origin Enterprises Reissues Treasury Shares to Meet Incentive Plan Options

In a report released today, Tim Long from Barclays downgraded Logitech to a Hold, with a price target of $98.00. Long covers the Technology sector,...

Barclays downgrades Logitech (LOGI) to a Hold

In a report released today, from Canaccord Genuity reiterated a Buy rating on Empire Metals, with a price target of p62.00. Empire Metals has an an...

Canaccord Genuity Sticks to Its Buy Rating for Empire Metals (EEE)

In a report released on January 7, Torsten Sauter from Kepler Capital maintained a Buy rating on Logitech, with a price target of CHF105.00. The co...

Kepler Capital  Sticks to Their Buy Rating for Logitech (LOGI)

UBS analyst Joern Iffert maintained a Buy rating on Logitech today and set a price target of CHF94.00. Iffert covers the Industrials sector, focusi...

Current Quarter	$0.71	Next Quarter	$NA
Current Year	$3.6	Next Year	$3.63
QoQ Growth	NaN%	YoY Growth	+0.8%
3Y EPS CAGR	-14.3%	Target Price	$9.93
Consensus	Buy	Upside	+22.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OGN	$8.12	-1.04%	2.92M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OGN	$8.12	-1.0%	2.92M
3
4
5
6

OGN

OGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Organon & Co. Data in Excel

Get Organon & Co. Data in Excel